Cefpodoxime proxetil
Cefpodoxime proxetil is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please sign in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Upper respiratory tract infections including acute otitis media, pharyngitis, tonsillitis, acute exacerbation of chronic bronchitis (AECB), and acute maxillary sinusitis
- Acute uncomplicated urethral and cervical gonorrhea and ano-rectal gonorrhea (females) caused by N. gonorrhoeae (no longer recommended by CDC) [3]
- Uncomplicated skin and skin-structure infections S. aureus (MSSA) or S. pyogenes.
- Uncomplicated urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilis, or S. saprophyticus.
- Community-acquired pneumonia (CAP) caused by S. pneumoniae or H. influenzae
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
- Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
- IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first[1].
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
INDICATIONS
FDA
FDA
- Upper respiratory tract infections including acute otitis media, pharyngitis, tonsillitis, acute exacerbation of chronic bronchitis (AECB), and acute maxillary sinusitis
- Acute uncomplicated urethral and cervical gonorrhea and ano-rectal gonorrhea (females) caused by N. gonorrhoeae (no longer recommended by CDC) [3]
- Uncomplicated skin and skin-structure infections S. aureus (MSSA) or S. pyogenes.
- Uncomplicated urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilis, or S. saprophyticus.
- Community-acquired pneumonia (CAP) caused by S. pneumoniae or H. influenzae
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
- Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
- IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first[1].
There's more to see -- the rest of this entry is available only to subscribers.